Atiquine P50 500 mg/g pulveris iekšķīgai lietošanai Lotyšsko - lotyština - Pārtikas un veterinārais dienests, Zemkopības ministrija

atiquine p50 500 mg/g pulveris iekšķīgai lietošanai

fatro s.p.a., itālija - flumequine - pulveris iekšķīgai lietošanai - 500 mg/g - putni; zivis

Prezista Európska únia - lotyština - EMA (European Medicines Agency)

prezista

janssen-cilag international nv - darunavir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Rezolsta Európska únia - lotyština - EMA (European Medicines Agency)

rezolsta

janssen-cilag international n.v. - darunavir, cobicistat - hiv infekcijas - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta ir indicēts kombinācijā ar citām pretretrovīrusu zālēm cilvēka imūndeficīta vīrusa (hiv 1) infekcijas ārstēšanai pieaugušajiem no 18 gadu vecuma. genotypic testēšana būtu ceļvedis, lietošanas rezolsta.

Symtuza Európska únia - lotyština - EMA (European Medicines Agency)

symtuza

janssen-cilag international nv - darunavir, cobicistat, emtricitabine, tenofovir alafenamide - hiv infekcijas - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza indicēts cilvēka imūndeficīta vīrusa 1. tipa (hiv-1) infekcijas ārstēšanai pieaugušajiem un pusaudžiem (no 12 gadu vecuma un vecākiem ar ķermeņa svaru vismaz 40 kg). genotypic testing should guide the use of symtuza.

Stomagels 5 mg/20 mg/g gels Lotyšsko - lotyština - Zāļu valsts aģentūra

stomagels 5 mg/20 mg/g gels

lmp, sia, latvia - methyluracilum, lidocainum - gels - 5 mg/20 mg/g

Fastum 2,5% gels Lotyšsko - lotyština - Zāļu valsts aģentūra

fastum 2,5% gels

a. menarini industrie farmaceutiche riunite s.r.l., italy - ketoprofēns - gels - 2,5%

Apiguard 250 mg/g gels lietošanai stropos Lotyšsko - lotyština - Pārtikas un veterinārais dienests, Zemkopības ministrija

apiguard 250 mg/g gels lietošanai stropos

vita bee health limited, Īrija - timols - gels lietošanai stropos - 250 mg/g - bites

Tetroxy L.A. 200 mg/ml šķīdums injekcijām Lotyšsko - lotyština - Pārtikas un veterinārais dienests, Zemkopības ministrija

tetroxy l.a. 200 mg/ml šķīdums injekcijām

bimeda animal health limited, Īrija - oksitetraciklīns dihidrāts - šķīdums injekcijām - 200 mg/ml - aitas; cūkas; liellopi

LV Biocillin-150 LA 150 mg/ml suspensija injekcijām Lotyšsko - lotyština - Pārtikas un veterinārais dienests, Zemkopības ministrija

lv biocillin-150 la 150 mg/ml suspensija injekcijām

interchemie werken de adelaar eesti as, igaunija - amoksicilīna trihidrāts - suspensija injekcijām - 150 mg/ml - aitas; cūkas; kazas; liellopi; teļi

Pirox 5 mg/g gels Lotyšsko - lotyština - Zāļu valsts aģentūra

pirox 5 mg/g gels

unifarma, sia, latvija - piroksikāms - gels - 5 mg/g